LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07. Submission of Matters to a Vote of Security
Holders.
On June22, 2017, the Company held its 2017 Annual Meeting of
Stockholders (Annual Meeting) and the following proposals were
adopted:
1. Election of three ClassIII directors, Steven A. Elms, Alan
Fuhrman and Avi Z. Naider, each to serve a three-year term, which
will expire at the 2020 Annual Meeting of Stockholders or until
such time as their respective successors have been duly elected
and qualified:
|
Nominees |
|
SharesFor |
|
SharesWithheld |
|
SharesAbstaining |
|
BrokerNon-Votes |
|
|
Steven A. Elms |
16,944,458 |
3,810,289 |
|
3,868,022 |
|||||
|
Alan Fuhrman |
17,586,064 |
3,168,683 |
|
3,868,022 |
|||||
|
Avi Z. Naider |
17,585,444 |
3,169,303 |
|
3,868,022 |
2. Ratification of the appointment of Ernst Young LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017:
|
SharesFor |
|
SharesAgainst |
|
SharesAbstaining |
|
BrokerNon-Votes |
|
|
24,617,366 |
4,403 |
1,000 |
|
About LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity. LOXO ONCOLOGY, INC. (NASDAQ:LOXO) Recent Trading Information
LOXO ONCOLOGY, INC. (NASDAQ:LOXO) closed its last trading session up +0.99 at 81.16 with 900,548 shares trading hands.